A Phase 1 Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Candidate Human Cytomegalovirus Vaccine (VBI-1501) in Healthy Adults

Trial Profile

A Phase 1 Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Candidate Human Cytomegalovirus Vaccine (VBI-1501) in Healthy Adults

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Cytomegalovirus vaccine (Primary)
  • Indications Cytomegalovirus infections
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors VBI Vaccines
  • Most Recent Events

    • 27 Jul 2017 According to a a VBI Vaccines media release, final safety and immunogenicity data is expected in the first half of 2018.
    • 27 Jul 2017 Interim results were published in a VBI Vaccines media release.
    • 02 May 2017 According to a VBI Vaccines media release, upon review of all safety data up to one month after second immunizations in this clinical study, the Data and Safety Monitoring Board (DSMB) has unanimously recommended the continuation of the study without modification.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top